Free shipping on all orders over $ 500


Cat. No. M3722
Temsirolimus Structure

CCI-779; WAY-130779

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 110  USD110 In stock
5mg USD 60  USD60 In stock
10mg USD 80  USD80 In stock
50mg USD 340  USD340 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Temsirolimus (CCI-779) inhibited the growth of xenografts derived from both cell lines with greater effects against PC-3 than DU145 tumors. Temsirolimus caused mild myelosuppression. The activity of mitoxantrone or docetaxel was limited, but CCI-779 given between courses of chemotherapy increased growth delay of PC-3 xenografts. High-dose temsirolimus inhibits mTOR signaling through an FKBP12-independent mechanism that leads to profound translational repression. This distinctive high-dose compound effect could be directly related to the antitumor activities of temsirolimus and other rapalogues in human cancer patients. The rapamycin analogue CCI-779 is an important new agent to investigate in the treatment of human brain tumors, particularly PNET/MB. The rapamycin analogue temsirolimus improved performance on four different behavioral tasks and decreased aggregate formation in a mouse model of Huntington disease.

Product Citations
Customer Product Validations & Biological Datas
Source Cell Death & Disease (2018). Figure 2. Temsirolimus (Abmole Bioscience)
Method colony formation assays
Cell Lines MDA-MB-231, MDA-MB-157, and MDA-MB-468 cells
Concentrations 1 μM
Incubation Time 24 h
Results But treatment with Temsirolimus in combination with ABT263 or ABT199 only induced modest cell viability inhibition.
Source Cell Death & Disease (2018). Figure 1. Temsirolimus (Abmole Bioscience)
Method Immunoblotting analysis
Cell Lines TNBC cell lines
Concentrations 1 μM
Incubation Time 24 h
Results As expected, we found the mTOR inhibitors, especially the BEZ235 and AZD8055, could significantly inhibit the phosphorylation of AKT and 4EBP1 and efficiently led to decreasing MCL-1 expression.
Source APMIS.m (2017). Figure 7. temsirolimus (Abmole Bioscience Inc. Houston, TX, USA)
Method Western blot
Cell Lines HeLa cells
Incubation Time
Results In addition, exposure with deguelin and temsirolimus could weaken the inhibitory attributes of 10-G on the expression of p-AKT and p-mTOR.
Protocol (for reference only)
Cell Experiment
Cell lines A549, H157, H460, H446, HCT116, HT29, SW480, DLD1, Caco2, LNCap, DU145, MDA468, MDA231, HEK293, and PC3-MM2
Preparation method Exposing cells to various concentrations of Temsirolimus for 72 hours. After treatment, using CellTiter AQ assay kit to determing viable cell densities by MTS dye conversion.
Concentrations Dissolved in DMSO, final concentrations ~20 μM
Incubation time 72 hours
Animal Experiment
Animal models Female athymic nude mice injected s.c. with DAOY, or U251 cells
Formulation Prepared in 100% EtOH as a 50 mg/mL stock solution, and diluted in 5% Tween 80 and 5% polyethylene glycol 400
Dosages 20 mg/kg
Administration Injection daily 5 times per week
Chemical Information
Molecular Weight 1030.29
Formula C56H87NO16
CAS Number 162635-04-3
Solubility (25°C) DMSO ≥40 mg/mL
Ethanol ≥50 mg/mL
Storage -20°C, protect from light, sealed
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Shor B, et al. Cancer Res. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.

[2] Wu L, et al. Cancer Res. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.

[3] Ravikumar B, et al. Nat Genet. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease.

[4] Geoerger B, et al. Cancer Res. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.

Related mTOR Products
Thioether-cyclized helix B peptide, CHBP

Thioether-cyclized helix B peptide, CHBP can improve metabolic stability and renoprotective effect through inducing autophagy via inhibition of mTORC1 and activation of mTORC2.

10-Hydroxy-2-decenoic acid

10-Hydroxy-2-decenoic acid (10-HDA) is the major lipid component of royal jelly produced by honeybees.

mTOR inhibitor-11

mTOR inhibitor-11 is a brain-penetrant mTOR inhibitor (IC50: 21 nM for pS6).

mTOR inhibitor-12

mTOR inhibitor-12 is a selective brain penetrant mTOR inhibitor without genotoxicity risk.


Royleanone, a diterpenoid isolated from plants, inhibits the proliferation of cancer cells by inducing cell cycle arrest and mitochondria-mediated apoptosis.

Abmole Inhibitor Catalog

Keywords: Temsirolimus, CCI-779; WAY-130779 supplier, mTOR, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.